EnterNext welcomes Abivax on Euronext in Paris - Dr. Hartmut Ehrlich, CEO, Abivax 00:00:00

Share On Facebook Share On Twitter

Abivax specializes in the research, development and commercialization of anti-viral drugs and therapeutic vaccines for the treatment of severe infectious diseases.

Recent Videos